Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
Por:
Richardson, PG, Oriol, A, Larocca, A, Otero, PR, Moreb, J, Blade, J, Hassoun, H, Cavo, M, Alegre, A, Mazumder, A, Maisel, C, Paner, A, Leleu, X, Zonder, JA, Harmenberg, J, Thuresson, S, Zubair, H and Mateos, MV
Publicada:
1 jul 2019
Resumen:
Filiaciones:
Richardson, PG:
Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
:
Hosp Badalona Germans Trias & Pujol, Badalona, Spain
Larocca, A:
AOUCitta Salute & Sci Torino SC Ematol U, Turin, Italy
Otero, PR:
Clin Univ Navarra, Pamplona, Spain
Moreb, J:
Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
Blade, J:
Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain
Hassoun, H:
Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
Cavo, M:
St Orsola Marcello Malpighi Hosp, Bologna, Italy
Alegre, A:
Hosp Univ La Princesa, Madrid, Spain
Mazumder, A:
Innovat Clin Res Inst, Whittier, CA USA
Maisel, C:
Baylor Scott & White Charles A Sammons Canc Ctr, Dallas, TX USA
Paner, A:
Rush Univ, Med Ctr, Chicago, IL 60612 USA
Leleu, X:
CHU Poitiers, Poitiers, France
Zonder, JA:
Karmanos Canc Inst, Detroit, MI USA
Harmenberg, J:
Oncopeptides AB, Stockholm, Sweden
Thuresson, S:
Oncopeptides AB, Stockholm, Sweden
Zubair, H:
Oncopeptides AB, Stockholm, Sweden
Mateos, MV:
Hosp Clin Univ Salamanca, Salamanca, Spain
|